Esperion Therapeutics (NASDAQ:ESPR) Upgraded at ValuEngine

ValuEngine upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research report released on Wednesday morning, ValuEngine reports.

ESPR has been the subject of several other research reports. Goldman Sachs Group upgraded shares of Esperion Therapeutics from a sell rating to a neutral rating and decreased their target price for the stock from $55.00 to $45.00 in a research report on Monday, September 16th. Stifel Nicolaus decreased their target price on shares of Esperion Therapeutics from $112.00 to $70.00 and set a buy rating for the company in a research report on Tuesday, September 17th. Northland Securities restated a buy rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. BidaskClub cut shares of Esperion Therapeutics from a sell rating to a strong sell rating in a research report on Wednesday, July 31st. Finally, Cowen restated a buy rating and issued a $80.00 target price on shares of Esperion Therapeutics in a research report on Thursday, July 18th. Two analysts have rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and an average target price of $71.60.

NASDAQ ESPR traded up $0.03 on Wednesday, hitting $37.52. The stock had a trading volume of 164,277 shares, compared to its average volume of 389,809. Esperion Therapeutics has a one year low of $33.13 and a one year high of $60.99. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -4.98 and a beta of 1.89. The company’s 50-day moving average is $36.79 and its two-hundred day moving average is $43.11.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.86) by ($0.15). The business had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $1.05 million. During the same period last year, the business posted ($1.71) EPS. The company’s revenue was up 9720.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Esperion Therapeutics will post -3.02 earnings per share for the current year.

In related news, major shareholder Target N. V. Biotech purchased 50,000 shares of Esperion Therapeutics stock in a transaction dated Tuesday, July 23rd. The stock was bought at an average cost of $42.65 per share, with a total value of $2,132,500.00. Following the purchase, the insider now owns 3,572,964 shares in the company, valued at approximately $152,386,914.60. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Target N. V. Biotech purchased 80,000 shares of Esperion Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $33.78 per share, with a total value of $2,702,400.00. Following the completion of the purchase, the insider now owns 3,652,964 shares in the company, valued at approximately $123,397,123.92. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 142,500 shares of company stock valued at $5,291,825. Company insiders own 7.70% of the company’s stock.

Several large investors have recently modified their holdings of ESPR. NumerixS Investment Technologies Inc acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $280,000. Dynamic Technology Lab Private Ltd acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $329,000. Marshall Wace LLP acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $186,000. Marshall Wace North America L.P. acquired a new stake in Esperion Therapeutics during the first quarter valued at approximately $164,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in Esperion Therapeutics during the second quarter valued at approximately $203,000.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: What is Blockchain?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.